This Cancer Tumor Profiling market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.
The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.33 billion in 2029 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (ai) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.
The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.
The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.
Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformitè Europëenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.
In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.
In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid.
Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.
The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.
The cancer tumor profiling market research report is one of a series of new reports that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.
The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.33 billion in 2029 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (ai) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.
The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.
The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.
Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformitè Europëenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.
In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.
In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid.
Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.
The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.
The cancer tumor profiling market research report is one of a series of new reports that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cancer Tumor Profiling Market Characteristics3. Cancer Tumor Profiling Market Trends and Strategies4. Cancer Tumor Profiling Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Cancer Tumor Profiling Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Cancer Tumor Profiling Market34. Recent Developments in the Cancer Tumor Profiling Market
5. Global Cancer Tumor Profiling Growth Analysis and Strategic Analysis Framework
6. Cancer Tumor Profiling Market Segmentation
7. Cancer Tumor Profiling Market Regional and Country Analysis
8. Asia-Pacific Cancer Tumor Profiling Market
9. China Cancer Tumor Profiling Market
10. India Cancer Tumor Profiling Market
11. Japan Cancer Tumor Profiling Market
12. Australia Cancer Tumor Profiling Market
13. Indonesia Cancer Tumor Profiling Market
14. South Korea Cancer Tumor Profiling Market
15. Western Europe Cancer Tumor Profiling Market
16. UK Cancer Tumor Profiling Market
17. Germany Cancer Tumor Profiling Market
18. France Cancer Tumor Profiling Market
19. Italy Cancer Tumor Profiling Market
20. Spain Cancer Tumor Profiling Market
21. Eastern Europe Cancer Tumor Profiling Market
22. Russia Cancer Tumor Profiling Market
23. North America Cancer Tumor Profiling Market
24. USA Cancer Tumor Profiling Market
25. Canada Cancer Tumor Profiling Market
26. South America Cancer Tumor Profiling Market
27. Brazil Cancer Tumor Profiling Market
28. Middle East Cancer Tumor Profiling Market
29. Africa Cancer Tumor Profiling Market
30. Cancer Tumor Profiling Market Competitive Landscape and Company Profiles
31. Cancer Tumor Profiling Market Other Major and Innovative Companies
35. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cancer Tumor Profiling Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cancer tumor profiling? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer tumor profiling market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
Key Companies Mentioned: F. Hoffmann-La Roche Ltd.; Caris Life Sciences; Thermo Fisher Scientific Inc.; Illumina Inc.; Qiagen
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Cancer Tumor Profiling market report include:- F. Hoffmann-La Roche Ltd.
- Caris Life Sciences
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Qiagen
- Ribomed Biotechnologies Inc.
- HTG Molecular Diagnostics Inc.
- NanoString Technologies Inc.
- NeoGenomics Laboratories Inc.
- Lucence Health Inc.
- ACT Genomics Co. LTD
- Strand Life Sciences
- IMB Dx Inc.
- Exact Sciences Corporation
- Guardant Health
- Foundation Medicine Inc.
- Agilent Technologies Inc.
- Myriad Genetics Inc.
- Personal Genome Diagnostics Inc.
- Tempus Labs Inc.
- ArcherDX Inc.
- Natera Inc.
- Bio-Rad Laboratories Inc.
- Genetron Health
- NantHealth Inc.
- Resolution Bioscience
- Genomic Testing Cooperative
- OncoDNA
- Strata Oncology Inc.
- Genuity Science
- RareCyte Inc.
- Inivata Limited
- Cepheid
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 14.99 Billion |
| Forecasted Market Value ( USD | $ 25.33 Billion |
| Compound Annual Growth Rate | 14.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
